| Date | Title | Description |
| 03.10.2024 | Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust | CAMBRIDGE, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced the sale of certain future license fees and other payments owed to Editas Medicine under its Ca... |
| 14.05.2024 | CRISPR на практике. Восстанавливая зрение | Буквально на днях публиковал новость о том, что в мир вышла нейросеть, которая предлагает немалый потенциал для развития биотехнологий. И что возможности современной медицины постепенно расширяются. Что ж, мир технологий и правда не стоит н... |
| 06.05.2024 | CRISPR Gene Editing Shows Promise: Early Trial Improves Vision in Blind Children | Quincy Jon, Tech Times 06 May 2024, 07:05 pm
An early-stage clinical experiment published in the New England Journal of Medicine found that gene therapy can improve hereditary blindness.
Researchers from the Children's Hospital of Philadelp... |
| 01.04.2024 | Впервые в мире почку свиньи изменили генетически и пересадили человеку. Теперь их можно массово пересаживать... | Хирурги из США провели человеку трансплантацию почки, полученной из генетически модифицированной свиньи. СМИ сообщают, что данная операция является прорывом в области ксенотрансплантации, когда органы, клетки или ткани пересаживаются из одн... |
| 08.03.2024 | CRISPR Technology Takes Center Stage at SXSW 2024 for the First Time | - |
| 11.02.2022 | With sotrovimab in the balance, Biogen vet reunites with George Scangos at Vir; First woman to chair PhRMA has more in store at Takeda | Johanna Friedl-Naderer
Vir Biotechnology is getting another Biogen vet to join up as the startup’s new global CBO and EVP.
While Johanna Friedl-Naderer officially doesn’t start her first C-suite role for another few weeks on March 2, she wi... |
| 29.09.2021 | Editas Medicine : Review of BRILLIANCE Phase 1/2 Single Ascending Dose Study of EDIT-101 Presentation | BRILLIANCE: A Phase 1/2 Single Ascending Dose Study of EDIT-101,
an in vivo CRISPR Gene Editing Therapy in CEP290-Related Retinal Degeneration
September 29, 2021
Forward Looking Statements
This presentation contains forward-looking statemen... |
| 07.10.2020 | ‘A terrific choice’: George Church salutes fellow CRISPR pioneers’ historic Nobel win | George Church, who is in the thick of both the science and the business of editing genomes with the now Nobel-Prize-winning technology called CRISPR, warmly greeted Wednesday’s award in chemistry to fellow pioneers Emmanuelle Charpentier an... |
| 16.10.2019 | Amarna raises €10M to push gene therapy platform into clinic; Editas Medicine, AskBio join forces | → Amarna Therapeutics — developing an SV40-based gene delivery vector platform called SVac — has raised €10 million. The round was led by Swedish investment company Flerie Invest AB, along with contributions from the Net... |
| 26.07.2019 | Editas, Allergan open first trial of in vivo CRISPR therapy | Last month, Chicago-based AbbVie said it would acquire Allergan – best known for manufacturing drugs like Botox (onabotulinumtoxinA) – for $63 billion.
LCA10 is caused by mutations in the CEP290 gene and is one of several subtypes of LCA. L... |
| 22.01.2019 | Editas Medicine CEO steps down as company moves into product development stage | Editas’s stock fell more than 20 percent on the Nasdaq Tuesday morning following the announcement. The news dragged other gene-editing shares down as well. Switzerland-based Crispr Therapeutics’ shares, which also trade on the Nasdaq, fell ... |
| 28.12.2018 | Andrew Hack to Join Bain Capital as a Managing Director | CAMBRIDGE, Mass., Dec. 21, 2018 (GLOBE NEWSWIRE) — Editas Medicine, Inc.(NASDAQ: EDIT), a leading genome editing company, today announced that its Chief Financial Officer, Andrew Hack, M.D., Ph.D., will be stepping down from the Company, ef... |
| 17.07.2018 | New challenge filed to CRISPR patent licensed by Editas Medicine | Another key patent on the CRISPR genome editing technology is facing a legal challenge. On Tuesday, St. Louis-based Benson Hill Biosystems, a privately held agriculture biotech company, filed a petition for post-grant review with the U.S. P... |
| 15.02.2018 | With new CRISPR inventions, its pioneers say, you ain’t seen nothin’ yet | No one would be surprised if scientists announced tomorrow that CRISPR had leapt tall test tubes in a single bound, but until that happens, fans of the superhero genome-editing system will have to be content with a trio of almost-as-flashy ... |
| 12.09.2017 | 23andMe raises $250M led by Sequoia Capital | Others in the genomics space that have raised funding include Counsyl, Veritas and Sophia
It's been 17 years since the Human Genome Project, led by Dr. Craig Venter, announced the mapping of the human genome, a breakthrough in science that ... |
| 26.06.2017 | Who will pay for CRISPR? | The ruckus over the CRISPR gene-editing system hides a dark reality: its high cost may make it unaffordable and questions remain whether most insurance companies will pay for it.
As CRISPR begins to move forward in clinical trials, there ar... |
| 25.04.2017 | The Broad Institute is testing the limits of what ‘nonprofit’ means | When a federal patent court ruled that the nonprofit Broad Institute of MIT and Harvard could legally license its version of the CRISPR-Cas9 genome-editing system, it opened the door to millions of dollars of revenue for the institute. It a... |
| 03.03.2017 | Why does anybody own CRISPR? An argument against academic IP | Why does anybody own CRISPR?
His point: Intellectual property in academia is a drain on the system. It’s a model that was ushered in decades ago with an aim to encourage innovation. Instead, it stifles the academic process with licensing co... |
| 15.02.2017 | Editas breathes sigh of relief as CRISPR ruling handed down | This means that although the Broad patents were filed after the University of California’s, they are deemed to cover their own intellectual real estate. The two patents can theoretically coexist.
Wednesday’s decision is a win for The Broad ... |
| 30.01.2017 | Is innovation a kind of intellectual immigration? | “The word pioneering for us is not an adjective, it’s not a compliment, it’s basically a verb,” said Noubar Afeyan, Flagship’s CEO and senior managing partner. “It is a process, it is kind of consciously looking for value in unexplored plac... |
| 07.12.2016 | Kendall Square’s boarding school for biotechs | Mass Innovation Labs was late to the game, opening in May 2015. But it is clearly doing something different.
According to CEO Amrit Chaudhuri, graduates of Mass Innovation Lab’s program have collectively licensed and raised over $4 billion.... |
| 31.10.2016 | Third Rock Ventures closes $616 million healthcare fund | Fund IV has not yet begun investing, according to a company representative, but the firm has established a strong track record with its first three funds. In less than 10 years, Third Rock has invested in 40 companies, advancing 40 clinical... |
| 22.09.2016 | Monsanto licenses CRISPR technology to modify crops — with key restrictions | Agriculture giant Monsanto has licensed CRISPR-Cas9 genome-editing technology from the Broad Institute for use in seed development, the company announced on Thursday, a step that will likely accelerate and simplify the creation of crops tha... |
| 22.08.2016 | Protocols: Editas recruits a Bristol-Myers vet as CSO; Eli Lilly gets a dubious honor for Alzheimer's drug; Voyager in the spotlight | Cambridge, MA-based gene editing stalwart Editas has recruited a Bristol-Myers vet for the CSO’s job. Charles Albright moves in after a stint as VP of genetically defined diseases and genomics at Bristol-Myers.
Eli Lill... |
| 16.08.2016 | CRISPR patent fight: The legal bills are soaring | The meter is running like mad on the dispute over key patents on CRISPR genome editing. In its latest 10-Q filing with the Securities and Exchange Commission, Editas Medicine — which has licensed one of the patents in question — disclosed t... |
| 28.07.2016 | Protocols: Editas gets a gene editing collaborator; Regulus hustling up response to clinical hold; Sanofi drug OK’d | Gene editing pioneer Editas has signed on with the experts at the San Raffaele Telethon Institute for Gene Therapy (SR-TIGET) on a new alliance to research and develop genome edited hematopoietic stem cell and T cell ther... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| 17.06.2016 | Philanthropist Bill Gates talks public health, biotech, and the race for the White House | Bill Gates became one of the richest men in history after cofounding Microsoft. His impact on the world of personal computing cannot be overstated.
But for more than 15 years, he has devoted himself to philanthropic work through the Bill &a... |
| 09.03.2016 | Editas biotech stock drops by 26 percent over CRISPR patent dispute | Gene editing outfit Editas has been one of the most successful tech IPOs of 2016 so far, with shares skyrocketing up 130 percent shortly after the company’s public debut. But the stock has now plummeted nearly 26 percent in after-hours trad... |
| 25.01.2016 | CRISPR player Editas Medicine sets terms for $122M IPO | This is a relatively small fundraise, considering the fact that just five months ago it raised an impressive $120 million Series B round – with a notable backer including Bill Gates. It was founded in 2013 with a $43 million Series A.
Edita... |
| 05.01.2016 | Advances in gene editing, and hype, underlie Editas move to go public | The public is only now hearing about the stunning potential of genome editing to treat diseases, and scientists are barely three years into using one of the hottest editing techniques for basic research.
So the announcement on Monday that a... |
| 05.01.2016 | These infographics outline Editas’ post-IPO strategy | Here’s an interesting infographic from the prospectus that outlines Editas’ plans for expansion, in a three-step plan. Each figure accounts for 5,000 patients with inherited diseases that could benefit from a therapy that corrects the disea... |
| 04.01.2016 | Biotech Startups Hit the Ground Running, With Six Filing IPO Plans Today | If we had to gamble on it, we’d bet the IPO market will be far more brisk this year than last year, which was the worst year for tech IPOs in particular since 2009.
Even still, it came as a bit of a surprise today when not one or three but ... |
| 07.12.2015 | Google Ventures CEO: Our focus on the life sciences will grow | That said, Google Ventures, newly christened “GV” per its new website, will reduce its investments in seed-stage startups, Maris told the Wall Street Journal. This is right in line with current life sciences investment practices, in which t... |
| 06.11.2015 | Watch: Meet one of the world’s most groundbreaking scientists. He’s 34.
CRISPR studies by year and country | As the dish of steamed chicken feet clattered onto the table, an impish toddler drummed with her chop sticks. Nobody in the noisy restaurant in Boston’s Chinatown gave a second glance at the man dressed in a polo shirt and jeans enjoying di... |
| 11.08.2015 | CRISPR: Editas’ $120M proves it isn’t a bunch of hype. Here are 6 more biotechs shaping CRISPR landscape | But that’s already turned quickly on its head.
Confidence is growing in the technology, as evidenced by the title of a fantastic Wired article: “Easy DNA Editing Will Remake the World. Buckle Up.” And the broader scientific community is now... |
| 10.08.2015 | Editas Medicine Raises $120M in Series B Financing (Update) | Editas Medicine, a Cambridge, MA-based genome editing company, raised $120m in Series B private financing.
The round was led by Boris Nikolic, M.D., managing director of bng0, a U.S.-based investment company that was formed to invest exclus... |
| 10.08.2015 | Gene-editing startup Editas just raised $120m from Bill Gates, Google Ventures and 12 other investors | |
| 10.08.2015 | Genome editing company Editas gets infused with $120M | Investors in the company include Google Ventures, Khosla Ventures and Bill Gates
We like to complain about the world a lot, but this really is such a cool time to be alive. We are coming up with amazing technology at a more rapid pace than ... |
| 10.08.2015 | Gates backs a $120M breakout round for CRISPR/Cas9 pioneers at Editas | Editas CEO Katrine Bosley
Editas quickly emerged as one of the first biotech upstarts with potentially game-changing gene editing technology in its hands. Now it's rounded up a $120 million megaround to speed its way through the next two ye... |
| 10.08.2015 | Editas Medicine Raises $120M in Series B |
CAMBRIDGE, MA, Leading genome editing company, today announced that it has raised $120 million in a highly oversubscribed Series B private financing.
>> Click here for more funding data on Editas Medicine
>> To export Editas... |
| 10.08.2015 | Daily funding roundup - August 10, 2015 | Editas Medicine Inc secured $120M; Turing Pharmaceuticals bagged $90M; Vainglory raised $26M
Editas Medicine Inc. raised $120 million from investors to support development of a technology that can precisely edit DNA and potentially treat fa... |
| 10.08.2015 | Editas Medicine Raises $20M in Venture Capital Funding | Editas Medicine, a Cambridge, MA-based developer of genome-editing technology, raised $20m in venture capital funding.
Backers included Deerfield Management Company, L.P.‘s Deerfield Healthcare Innovations Fund, L.P., and Deerfield Private ... |
| 23.06.2015 | Five conspicuous omissions from MIT Tech Review’s 50 smartest companies | …we did not have trouble finding big ideas. To make the list, a company must have truly innovative technology and a business model that is both practical and ambitious, with the result that it has set the agenda in its field over the past 1... |
| 13.05.2015 | The Genome Engineering Revolution | Ryan Clarke Contributor
More posts by this contributor
A Third Act For Biofuels
James Hyun Contributor
More posts by this contributor
A Third Act For Biofuels
Editor’s note: Ryan Clarke is a biochemistry PhD candidate with an interest in ge... |
| 26.11.2013 | Editas Medicine Launches with $43M in Series A |
CAMBRIDGE, MA, Transformative genome editing company, today announced it has secured a $43 million Series A financing led by Flagship Ventures, Polaris Partners and Third Rock Ventures with participation from Partners Innovation Fund.
&g... |
| 25.11.2013 | Editas Medicine Secures $43M Series A Financing | Editas Medicine, a Cambridge, MA-based genome editing company, secured a $43m Series A financing.
The round was led by Flagship Ventures, Polaris Partners and Third Rock Ventures with participation from Partners Innovation Fund.
Founded by ... |
| - | These infographics outline Editas’ post-IPO strategy | Cambridge gene editing startup Editas Medicine just filed for a $100 million IPO, marking it the first company that uses CRISPR technology to go public.
The company’s rise has been rapid: It was launched in 2013 with a $43 million Series A ... |
| - | Editas Medicine raises $94.4 million in year’s first IPO | - |
| - | Is innovation a kind of intellectual immigration? | With over 75 scientific ventures to its name, Flagship’s startup network has now generated 16 IPOs and $19 billion in aggregate value over 17 years.
Things were going well, but Flagship Pioneering (formerly Flagship Ventures) still felt the... |
| - | Editas breathes sigh of relief as CRISPR ruling handed down | A day after experts weighed in on the ethical concerns of CRISPR, the U.S. Patent Trial and Appeal Board (PTAB) has delivered its ruling on the high-profile patent interference case shadowing the field.
The three judges determined that ther... |
| - | After falling behind gene-editing rivals, Editas just got a much-needed win in the courtroom. Here's how it could shake up the CRISPR landscape. | Editas Medicine CEO James Mullen Editas Medicine This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
A US court sided with the Broad Institute in a patent fight over CRISPR gene-editing techn... |
| - | CRISPR: Editas’ $120M proves it isn’t a bunch of hype. Here are 6 more biotechs shaping CRISPR landscape | CRISPR/Cas9 gene editing has zoomed to the forefront of the biotech investment scape in the past year — punctuated this week by Editas Medicine‘s impressive $120 million fundraise. Looks like it’s no longer hype — there’s solid funding to p... |
| - | Five conspicuous omissions from MIT Tech Review’s 50 smartest companies | We know who made the cut in the latest MIT Technology Review list of the 50 Smartest Companies of 2015.
But there were a few conspicuous omissions – take Theranos, for instance, or Alexion Pharmaceuticals – from the otherwise meaty list of ... |
| - | Third Rock Ventures closes $616 million healthcare fund | Third Rock Ventures announced Monday that it had closed its fourth fund — it’s largest, Third Rock Ventures IV — for an oversubscribed $616 million.
The Boston, Massachusetts-based firm now has a total of $1.9 billion in assets under manage... |
| - | Google Ventures CEO: Our focus on the life sciences will grow | Nearly a third of Google Ventures‘ investments are in the life sciences, according to the firm’s president and CEO Bill Maris. It’s entering 2016 with $2.4 billion under management, Maris wrote in a blog – and says will continue to strength... |
| - | Kendall Square’s boarding school for biotechs | A communal area at the Mass Innovation Labs facility
It’s hard to get excited about a biotech shared-space in 2016.
Four years ago, it was an exciting and rapidly diversifying field. Now incubators are par for the course, with most Big Phar... |
| - | Editas, Allergan open first trial of in vivo CRISPR therapy | A clinical trial of a CRISPR/Cas9-based gene therapy in an inherited form of blindness is expected to dose its first patient in the second half of this year.
Cambridge, Massachusetts-based Editas Medicine and Dublin-based Allergan said Thur... |
| - | Editas Medicine CEO steps down as company moves into product development stage | Shares of companies across the emerging field of gene editing fell Tuesday morning as one of the more prominent players said its chief executive would leave the firm.
Cambridge, Massachusetts-based Editas Medicine said Tuesday morning that ... |
| - | CRISPR player Editas Medicine sets terms for $122M IPO | CRISPR gene editing player Editas Medicine just set the terms for its forthcoming IPO, according to a new regulatory filing.
The Cambridge-based startup will offer 5.9 million shares, priced between $16 to $18 to raise an upsized $122 milli... |
| - | Why does anybody own CRISPR? An argument against academic IP | Who owns CRISPR?
It has – and continues to be – one of the biggest intellectual property debates in the history of science. But to Berkeley Professor Michael Eisen, the field is posing the wrong question. On Thursday, at the Future of Genom... |
| - | Билл Гейтс вложился в редактирование ДНК | Богатейший человек в мире Билл Гейтс инвестировал в компанию Editas Medicine, занимающуюся разработкой нашумевшей технологии редактирования генома CRISPR/Cas9.
В состоявшемся раунде инвестиций Editas Medicine привлекла в целом $120 млн. Лид... |
